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The 6-anilinouracils are novel dGTP analogs that selectively inhibit the replication-specific DNA polymerase
III of gram-positive eubacteria. Two specific derivatives, IMAU (6-[3*-iodo-4*-methylanilino]uracil) and
EMAU (6-[3*-ethyl-4*-methylanilino]uracil), were substituted with either a hydroxybutyl (HB) or a methoxy-
butyl (MB) group at their N3 positions to produce four agents: HB-EMAU, MB-EMAU, HB-IMAU, and
MB-IMAU. These four new agents inhibited Staphylococcus aureus, coagulase-negative staphylococci, Entero-
coccus faecalis, and Enterococcus faecium. Time-kill assays and broth dilution testing confirmed bactericidal
activity. These anilinouracil derivatives represent a novel class of antimicrobials with promising activities
against gram-positive bacteria that are resistant to currently available agents, validating replication-specific
DNA polymerase III as a new target for antimicrobial development.
New antibacterial agents are needed to combat the multiply
resistant gram-positive bacteria endemic in modern health care
facilities (15). The 6-anilinouracils (AUs) illustrated in Fig. 1
are selective inhibitors of DNA polymerase III-c2 (pol III), an
enzyme product of the polC gene (2, 8, 12). This enzyme is
essential for the replication of the chromosome in gram-posi-
tive bacteria (7, 9, 17) and is found in low-G1C-content eu-
bacteria, including staphylococci, enterococci, streptococci,
Listeria species, Bacillus species, and clostridia (1, 8). Briefly,
the AUs, inhibitors of the DNA pol III enzyme, act through
their capacity to mimic the guanine moiety of dGTP by form-
ing three hydrogen bonds with cytosine at one of the two active
domains (6, 7, 14). This leaves the second active site on the
inhibitor, the aryl domain, available to bind to DNA pol III,
which sequesters the enzyme into a nonproductive complex
with template primer DNA (19).
Structure-activity relationships of these AUs have been de-
scribed previously (18, 19). The prototypic AUs, which have
either weak antimicrobial activities or unacceptably low aque-
ous solubility (3–6, 13, 17), have now been substituted in their
N3 positions and aryl rings to produce a series of more potent
and more soluble molecules (13, 16, 19). The latest generation
of these soluble forms (19) includes the N3-hydroxybutyl (HB)
and N3-methoxybutyl (MB) derivatives of 6-[39-ethyl-49-methy-
lanilino]uracil (EMAU) and 6-[39-iodo-49-methylanilino]uracil
(IMAU) shown in Fig. 1. In this study, we describe the in vitro
activities of HB-IMAU, HB-EMAU, MB-IMAU, and MB-
EMAU against staphylococci and enterococci, bacteria that
are pathogenic in humans and are difficult to treat with cur-
rently available and investigational antimicrobial agents.
(This work was presented in part at the 39th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, Calif., 1999 [J. S. Daly, T. Giehl, N. C. Brown, C.
Zhi, G. E. Wright, and R. T. Ellison III, Abstr. 39th Intersci.
Conf. Antimicrob. Agents Chemother., abstr. 1808, 1999].)
Materials and methods. Bacterial strains used in this study
were unique clinical isolates collected in the clinical microbi-
ology laboratory at UMass Memorial Health Care, Worcester,
Mass. ATCC 29212 (Enterococcus faecalis) and ATCC 25923
(Staphylococcus aureus) were used as a control strains. Bacteria
were initially subcultured on agar plates containing 5% sheep
blood (PML Microbiologicals, Tulatin, Oreg.), heavy suspen-
sions were made in Trypticase soy broth (BBL, Becton Dick-
inson, Cockeysville, Md.) plus 15% glycerol, and the bacteria
were frozen at 270°C. Aliquots were taken and subcultured
overnight for susceptibility testing.
The following antibiotics were obtained from the sources
indicated: clindamycin and linezolid, Pharmacia Upjohn,
Kalamazoo, Mich.; quinupristin-dalfopristin, Rhoˆne-Poulenc
Rorer, Collegeville, Pa.; oxacillin, penicillin G, and rifampin,
Sigma Pharmaceuticals, St. Louis, Mo.; ofloxacin, Ortho-Mc-
Neil, Raritan, N.J.; and vancomycin, Eli Lilly & Co., Indianap-
olis, Ind. The pol III inhibitors HB-IMAU, HB-EMAU,
MB-IMAU, and MB-EMAU were synthesized by methods de-
scribed elsewhere (13, 19). The AUs were dissolved in di-
methyl sulfoxide and diluted in Mueller-Hinton broth (MH
broth; Difco, Detroit, Mich.) to a concentration of not higher
than 1% dimethyl sulfoxide. Microbroth dilution testing was
* Corresponding author. Mailing address: Division of Infectious
Diseases and Immunology, UMass Memorial Health Care, 55 Lake
Ave. N., Worcester, MA 01655. Phone: (508) 856-3158. Fax: (506)
856-5981. E-mail: dalyj01@ummhc.org.
† Present address: GLSynthesis, Inc., Worcester, MA 01605.
FIG. 1. Structures of the four AUs used in this study: HB-EMAU, HB-
IMAU, MB-EMAU, and MB-IMAU.
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TABLE 1. Activities of DNA pol III inhibitors and other antimicrobial agents against staphylococci and enterococci
Organism Relevant phenotype(no. of strains) Antimicrobial agent
MIC (mg/ml)a
50% 90% Range
S. aureus Oxacillin sensitive (15) HB-IMAU 16 16 8–32
HB-EMAU 8 16 8–16
MB-IMAU 8 16 4–16
MB-EMAU 8 16 4–16
Linezolid 1 2 0.5–4
Synercid 0.25 0.25 #0.125–0.25
Ofloxacin 0.5 16 #0.125–.16
Clindamycin 0.25 0.5 #0.125–4
Vancomycin 1 2 1–2
Rifampin #0.125 #0.125 #0.125–.16
Penicillin G 8 16 #0.125–.16
Oxacillin 0.5 2 #0.125–2
Oxacillin resistant (17) HB-IMAU 16 16 8–32
HB-EMAU 8 16 8–16
MB-IMAU 8 8 4–16
MB-EMAU 8 8 4–16
Linezolid 2 4 0.5–4
Synercid 0.25 0.5 0.25–1
Ofloxacin 16 .16 0.25–.16
Clindamycin .16 .16 #0.125–.16
Vancomycin 2 2 1–4
Rifampin #0.125 4 #0.125–16
Penicillin G .16 .16 4–.16
Oxacillin .8 .8 4–.8
Coagulase-negative
S. aureus
Oxacillin sensitive (15) HB-IMAU 16 32 4–32
HB-EMAU 8 16 4–16
MB-IMAU 8 16 4–16
MB-EMAU 8 8 4–16
Linezolid #0.125 2 #0.125–2
Synercid 0.25 0.5 #0.125–1
Ofloxacin 0.5 1 0.25–16
Clindamycin #0.125 0.5 #0.125–.16
Vancomycin #0.25 2 #0.25–4
Rifampin #0.125 #0.125 #0.125–.16
Penicillin G #0.125 4 #0.125–8
Oxacillin #0.125 2 #0.125–2
Oxacillin resistant (13) HB-IMAU 8 16 4–16
HB-EMAU 8 8 4–16
MB-IMAU 4 8 4–16
MB-EMAU 8 8 4–8
Linezolid 2 4 #0.125–4
Synercid #0.125 1 #0.125–2
Ofloxacin 16 .16 0.25–.16
Clindamycin .16 .16 #0.125–.16
Vancomycin 4 4 #0.25–8
Rifampin #0.125 .16 #0.125–.16
Penicillin G 8 .16 1–.16
Oxacillin .8 .8 4–.8
E. faecium Vancomycin sensitive (9) HB-IMAU 8 16 8–16
HB-EMAU 8 16 4–16
MB-IMAU 8 16 4–16
MB-EMAU 8 16 4–16
Linezolid 4 4 4
Synercid 1 4 1–4
Ofloxacin 4 .16 2–.16
Clindamycin 16 .16 8–.16
Vancomycin 8 16 1–16
Rifampin #0.125 16 #0.125–16
Penicillin G 2 .16 1–.16
Oxacillin .8 .8 .8
Continued on following page
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performed according to NCCLS standards (11) using MH
broth, which was supplemented with 2% NaCl in oxacillin-
containing wells for optimal growth of staphylococci. Antibi-
otic dilution plates were stored at 270°C and used within 12
weeks. Inocula were prepared by suspending growth from
overnight incubation on Trypticase soy agar (TSA; BBL) in 4
ml of normal saline to yield an optical density at 450 nm of 0.6
to 0.7 (2 3 108 CFU/ml). The optical density of each culture
was determined and compared to a standard growth curve. The
4-ml culture was diluted into 40 ml of saline for inoculating
thawed MIC trays (2 3 107 CFU/ml). Plates were inoculated
using a Dynatec MIC 2000 automatic inoculator to deliver the
cell suspension to each 100-ml well. Plates were incubated for
20 to 24 h at 37°C and were read at both 18 h and 20 to 24 h.
The number of colonies in at least one sample for each exper-
iment was verified to ensure that an inoculum of at least 5 3
105 CFU was obtained. The lowest concentration of each an-
tibiotic that prevented growth was recorded as the MIC. The
minimal bactericidal concentration (MBC) of each antibiotic
was determined by plating the entire 100-ml contents of the last
growth well and of each no-growth well onto a TSA plate.
After overnight incubation, the concentration of antibiotic that
gave 99.9% killing of the original inoculum was the MBC (10).
For time-kill assays, log-phase cultures in MH broth were
diluted to ;5 3 106 CFU/ml. One-milliliter test cultures were
prepared with controls or antibiotics in MH broth; the MH
broth was inoculated with 10% (100 ml) of the diluted culture
to yield $5 3 105 CFU/ml. Each test culture was sampled after
0, 2, 4, and 24 h of growth at 37°C. The culture samples were
diluted serially, plated onto TSA, and incubated for 48 h to
determine colony counts.
Results and discussion. Results of microbroth dilution stud-
ies are shown in Table 1. Respective MICs at which 90% of the
isolates tested were inhibited of HB-IMAU, HB-EMAU, MB-
IMAU, and MB-EMAU were as follows: 16, 16, 8, and 8 mg/ml
for oxacillin-resistant S. aureus isolates; 16, 16, 16, and 16
mg/ml for oxacillin-susceptible S. aureus isolates; 32, 16, 16, and
8 mg/ml for coagulase-negative–oxacillin-susceptible staphylo-
cocci; 16, 8, 8, and 8 mg/ml for coagulase-negative–oxacillin-
resistant staphylococci; 16, 8, 8, and 16 mg/ml for E. faecalis
isolates; 16, 16, 16, and 16 mg/ml for vancomycin-susceptible
Enterococcus faecium isolates; and 16, 16, 16, and 8 mg/ml for
vancomycin-resistant E. faecium isolates. The novel AUs in-
hibited most strains at a concentration of 8 to 16 mg/ml, with
there being no difference in the levels of activity against the
oxacillin-resistant staphylococci or the vancomycin-resistant
enterococci compared to those against the susceptible strains.
There was no cross-resistance between the AUs and other
inhibitors of DNA or RNA synthesis. The MICs for S. aureus
ATCC 25923 were 8 to 32 mg/ml, and the MBCs were identical
to the MICs for this strain in the cases of all four compounds.
For the enterococcal control strain ATCC 29212 MICs were 4
to 8 mg/ml and MBCs were two to four times higher. The AUs
were bactericidal to most of the clinical strains of staphylococci
at one to two times their MICs and to the enterococci at one
to four times their MICs. Time-kill assays, shown in Fig. 2
confirmed the bactericidal activities of HB-EMAU and MB-
IMAU.
HB-IMAU, HB-EMAU, MB-IMAU, and MB-EMAU are
new representatives of a class of compounds that inhibit a
novel target absolutely essential for the replication of the bac-
terial chromosome. These small molecules bind to the DNA
pol III of low-G1C-content gram-positive bacteria, including
staphylococci and enterococci, pathogenic bacteria that have
become increasingly resistant to currently available agents.
These AUs have in vitro activities against other species, in-
cluding Bacillus species and mycoplasmas, species that contain
the same target DNA pol III, but further study is needed (19).
TABLE 1—Continued
Organism Relevant phenotype(no. of strains) Antimicrobial agent
MIC (mg/ml)a
50% 90% Range
Vancomycin resistant (23) HB-IMAU 8 16 8–16
HB-EMAU 8 16 8–16
MB-IMAU 8 16 4–16
MB-EMAU 8 8 4–16
Linezolid 2 4 2–8
Synercid 1 1 0.25–1
Ofloxacin .16 .16 4–.16
Clindamycin .16 .16 0.25–.16
Vancomycin .32 .32 .32
Rifampin 8 8 #0.125–16
Penicillin G .16 .16 .16
Oxacillin .8 .8 .8
E. faecalis (32) HB-IMAU 8 16 4–16
HB-EMAU 8 8 4–8
MB-IMAU 8 8 2–16
MB-EMAU 8 16 4–16
Linezolid 2 4 2–4
Synercid 4 8 2–16
Ofloxacin 4 .16 1–.16
Clindamycin .16 .16 8–.16
Vancomycin 2 8 1–.32
Rifampin 4 8 0.5–16
Penicillin G 4 8 2–16
Oxacillin .8 .8 8–.8
a 50% and 90%, MICs at which 50 and 90% of the isolates tested were inhibited, respectively.
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They have no activity against the Enterobacteriaceae, as the
target DNA polymerase is not found in gram-negative bacteria.
Similarly, the target polymerase is not found in mammalian
cells and the AUs do not bind to the mammalian polymerase
alpha, the primary mammalian DNA polymerase (14). They
are unrelated to available agents, to compounds currently be-
ing tested in clinical trials, and to antimicrobials used in animal
feed. Two members of this class of antimicrobials, HB-IMAU
and HB-EMAU, have been shown to have activity in a lethal S.
aureus mouse peritonitis model, with 10 mg/kg of body weight
providing protection equal to that of vancomycin at 20 mg/kg
(19).
This study is the first to detail the in vitro activities of
members of this class of antimicrobial agents against clinical
isolates in comparison to those of available agents. There was
no cross-resistance between these AUs and the fluoroquinolo-
nes or rifampin, other inhibitors of DNA and RNA synthesis.
Similarly, no cross-resistance was detected with agents that
exert their antibacterial action at the level of cell wall or pro-
tein synthesis. The AUs were bactericidal at one to four times
their MICs for most strains.
The results of this study confirm the general hypothesis (14)
that bacterial DNA pol III is a valid target for antimicrobial
drug development, including the development of agents effec-
tive against clinically relevant organisms resistant to conven-
tional antimicrobials. More specifically, our results demon-
strate the strong potential of the AUs as model antibacterial
agents. Given their potential, new forms of these AUs are
under development with the objective of enhancing their aque-
ous solubility and in vitro potency, so that their safety and
efficacy can be assessed in vivo against infections with relevant
pathogens.
We thank Maureen Jankins, Brenda Torres, and Rosemary Dodge
at the Clinical Microbiology Lab, UMass Memorial Health Care, for
help with preparation of the MIC panels and collection of the bacterial
strains. We thank Pharmacia Upjohn and Rhoˆne-Poulenc Rorer for
providing antimicrobial reference powders.
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